Top

Published in:

01-07-2011 | Review Article

Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis

Authors: Kei Zaitsu, Munehiro Katagi, Michiaki Tatsuno, Takako Sato, Hitoshi Tsuchihashi, Koichi Suzuki

Published in: Forensic Toxicology | Issue 2/2011

Abstract

β-Keto derivatives of 3,4-methylenedioxyphenylalkylamines (bk-MDPAs), especially 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone), 2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB), and 2-ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (bk-MDEA), are abused as substitutes for 3,4-methylenedioxyphenylalkylamines in some countries, causing increased social problems. With the widespread abuse of bk-MDPAs, the analysis of bk-MDPAs and their metabolites in human specimens is quite important in forensic and clinical toxicology. In this review, the metabolisms of bk-MDPAs and simultaneous analytical methods for bk-MDPAs and their metabolites by gas chromatography–mass spectrometry, liquid chromatography–mass spectrometry, and liquid chromatography–tandem mass spectrometry are presented.

Shulgin AT (1978) Psychotomimetic drugs: structure–activity relationships. In: Iversen LL, Iversen SD, Snyder SH (eds) The handbook of psychopharmacology: stimulants, vol 11. Plenum, New York, pp 243–333

Buchanan JF, Brown CR (1988) ‘Designer Drugs’ a problem in clinical toxicology. Med Toxicol Adverse Drug Exp 3:1–17PubMed

Glennon RA (1989) Stimulus properties of hallucinogenic phenylalkylamines and related designer drugs: formulation of structure–activity relationships. In: Asghar K, Souza ED (eds) Pharmacology and toxicology of amphetamine and related designer drugs. NIDA Research Monograph 94, Superintendent of Documents, U.S. Government Printing Office, Washington D.C., pp 43–67

Dal Cason TA, Young R, Glennon RA (1997) Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogues. Pharmacol Biochem Behav 58:1109–1116PubMedCrossRef

Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (1998) A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT_2A receptor. J Med Chem 41:5148–5149PubMedCrossRef

Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRef

Kamata T, Katagi M, Tsuchihashi H (2010) Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan. Forensic Toxicol 28:1–8CrossRef

Zaitsu K, Katagi M, Kamata H, Nakanishi K, Shima N, Kamata T, Nishioka H, Miki A, Tatsuno M, Tsuchihashi H (2010) Simultaneous analysis of six novel hallucinogenic (tetrahydrobenzodifuranyl)aminoalkanes (FLYs) and (benzodifuranyl)aminoalkanes (DragonFLYs) by GC-MS, LC-MS, and LC-MS-MS. Forensic Toxicol 28:9–18CrossRef

Vardakou I, Pistos C, Spiliopoulou Ch (2010) Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197:157–162PubMedCrossRef

10.

Jacob P, Shulgin AT (1996) Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents. PCT International Applications, p 19

11.

Cozzi NV, Sievert MK, Shulgin AT, Jacob P, Ruoho AE (1998) Methcathinone and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone) selectively inhibit plasma membrane catecholamine-reuptake transporters. Soc Neurosci Abstr 24:381–388

12.

Cozzi NV, Sievert MK, Shulgin AT, Jacob P (1999) Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur J Pharmacol 381:63–69PubMedCrossRef

13.

Bossong MG, Van Dijk JP, Niesink RJ (2005) Methylone and mCPP, two new drugs of abuse? Addict Biol 10:321–323PubMedCrossRef

14.

Erowid (2010) The vaults of Erowid. http://www.erowid.org/chemicals/methylone/methylone_info1.shtml. Accessed Dec 2010

15.

Russell M, Sibley J, Bunyan J (2010) Methylone found in New Zealand party pills. TIAFT Bull 40:38–39

16.

Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuchihashi H (2006) Metabolism of recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36:709–723PubMedCrossRef

17.

Zaitsu K, Katagi M, Kamata HT, Kamata T, Shima N, Miki A, Tsuchihashi H, Mori Y (2009) Determination of the metabolites of new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188:131–139PubMedCrossRef

18.

Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225–1233PubMedCrossRef

19.

Springer D, Fritschi G, Maurer HH (2003) Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J Chromatogr B 793:377–388CrossRef

20.

Testa B, Beckett AH (1973) Metabolism and excretion of diethylpropion in man under acidic urine conditions. J Pharm Pharmacol 25:119–124PubMedCrossRef

21.

Milhailova M, Rosen A, Testa B, Beckett AH (1974) A pharmacokinetic investigation of distribution and elimination of diethylpropion and its metabolites in man. J Pharm Pharmacol 26:711–721CrossRef

22.

Brenneison R, Mathys K, Geisshusler S (1991) Determination of S-(−)-cathinone and its main metabolites R, S-(−)-norephedrine in human plasma by high-performance liquid chromatography and photodiode array detection. J Liq Chromatogr 14:271–286CrossRef

23.

Paul BD, Cole KA (2001) Cathinone (Khat) and methcathinone (CAT) in urine specimens. J Anal Toxicol 25:525–530PubMed

24.

Toennes SW, Kauert GF (2002) Excretion and detection of cathinone, cathine, and phenylpropanolamine in urine after kath chewing. Clin Chem 48:1715–1719PubMed

25.

Lim HK, Foltz RL (1989) Identification of metabolites of 3,4-(methylenedioxy)-methamphetamine in human urine. Chem Res Toxicol 2:142–143PubMedCrossRef

26.

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J (2004) Human pharmacology of MDMA pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137–144PubMedCrossRef

27.

Kamata HT, Shima N, Zaitsu K, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H (2007) Simultaneous analysis of new designer drug, methylone and its metabolites in urine by gas chromatography-mass spectrometry and liquid chromatography-electrospray ionization mass spectrometry. Jpn J Forensic Sci Technol 12:97–106CrossRef

28.

Shima N, Tsutsumi H, Kamata T, Nishikawa M, Katagi M, Miki A, Tsuchihashi H (2006) Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users’ urine. J Chromatogr B 830:64–70CrossRef

29.

Shima N, Kamata H, Katagi M, Tsuchihashi H, Sakuma T, Nemoto N (2007) Direct determination of glucuronide and sulfate of 4-hydroxy-3-methoxymethamphetamine, the main metabolite of MDMA, in human urine. J Chromatogr B 857:123–129CrossRef

30.

Berrang BD, Lewin AH, Ivy CF (1982) Enantiomeric α-aminopropiophenones (cathinone): preparation and investigation. J Org Chem 47:2643–2647CrossRef

31.

Togawa Y, Ohmori T, Tanaka K, Inoue T (1994) Analyses of new stimulants, methcathinone and cathinone. Rep Natl Res Inst Police Sci 47:77–84 (in Japanese with English abstract)

32.

Zaitsu K, Katagi M, Kamata HT, Miki A, Tsuchihashi H (2008) Discrimination and identification of regioisomeric β-keto analogues of 3,4-methylenedioxyamphetamines by gas chromatography-mass spectrometry. Forensic Toxicol 26:45–51CrossRef

33.

Zaitsu K, Katagi M, Kamata T, Kamata H, Shima N, Tsuchihashi H, Hayashi T, Kuroki H, Matoba R (2008) Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine. Forensic Sci Int 177:77–84PubMedCrossRef

34.

Zaitsu K, Katagi M, Kamata H, Kamata T, Shima N, Miki A, Iwamura T, Tsuchihashi H (2008) Discrimination and identification of the six aromatic positional isomers of trimethoxyamphetamine (TMA) by gas chromatography-mass spectrometry (GC-MS). J Mass Spectrom 43:528–534PubMedCrossRef

35.

Kanai K, Takekawa K, Kumamoto T, Ishikawa T, Ohmori T (2008) Simultaneous analysis of six phenethylamine-type designer drugs by TLC, LC-MS, and GC-MS. Forensic Toxicol 26:6–12CrossRef

36.

Kudo K, Ishida T, Hikiji W, Hayashida M, Uekusa K, Usumoto Y, Tsuji A, Ikeda N (2009) Construction of calibration-locking databases for rapid and reliable drug screening by gas chromatography-mass spectrometry. Forensic Toxicol 27:21–31CrossRef

37.

Kudo K, Ishida T, Hikiji W, Usumoto Y, Umehara T, Nagamatsu K, Tsuji A, Ikeda N (2010) Pattern of poisoning in Japan: selection of drugs and poisons for systematic toxicological analysis. Forensic Toxicol 28:25–32CrossRef

38.

Morita M, Ando H (1983) Analysis of methamphetamine and its metabolites in urine from a habitual user of the stimulant. EISEI KAGAKU 29:318–322 (in Japanese with English abstract)

39.

Maurer HH (2005) Advances in analytical toxicology: the current role of liquid chromatography–mass spectrometry in drug quantification in blood and oral fluid. Anal Bioanal Chem 381:110–118PubMedCrossRef

40.

Mueller CA, Weinmann W, Dresen S, Schreiber A, Gergov M (2005) Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching. Rapid Commun Mass Spectrom 19:1332–1338PubMedCrossRef

41.

Dresen S, Kempf J, Weinmann W (2006) Electrospray-ionization MS/MS library of drugs as database for method development and drug identification. Forensic Sci Int 161:86–91PubMedCrossRef

42.

Smith ML, Vorce SP, Holler JM, Shimomura E, Magluilo J, Jacobs AJ, Huestis MA (2007) Modern instrumental methods in forensic toxicology. J Anal Toxicol 31:237–253PubMed

43.

Katagi M, Zaitsu K, Shima N, Kamata H, Kamata T, Nakanishi K, Nishioka H, Miki A, Tsuchihashi H (2010) Metabolism and forensic toxicological analyses of the extensively abused designer drug methylone. TIAFT Bull 40:30–34

Title: Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis
Authors: Kei Zaitsu
Munehiro Katagi
Michiaki Tatsuno
Takako Sato
Hitoshi Tsuchihashi
Koichi Suzuki
Publication date: 01-07-2011
Publisher: Springer Japan
Published in: Forensic Toxicology / Issue 2/2011
Print ISSN: 1860-8965
Electronic ISSN: 1860-8973
DOI: https://doi.org/10.1007/s11419-011-0111-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recently abused β-keto derivatives of 3,4-methylenedioxyphenylalkylamines: a review of their metabolisms and toxicological analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Imaging of methamphetamine incorporated into hair by MALDI-TOF mass spectrometry

Mushroom toxins: a forensic toxicological review

Determination of acephate and methamidophos in tissues: appearance of matrix effect in gas chromatography–mass spectrometry

A model system for prediction of the in vivo metabolism of designer drugs using three-dimensional culture of rat and human hepatocytes

A study on mechanisms of toxic actions of ciguatoxins: existence of functional relationship between CTX3C and charged residues of voltage sensors in Nav1.4 sodium channel

Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids